Clinical trials: in Kuwait
Relapsing Remitting Multiple Sclerosis (RRMS)
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
The Study analyses the influence of selected factors on adherence to Betaferon treatment in patients with early multiple sclerosis (MS).
- Trial name
- BEACON (NCT00787657)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 36 sites in Argentina, Bahrain and 34 more
- Volunteers
- 1,723 people
- Sponsor
- Bayer
Hepatitis C, Chronic
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
This multicenter study will evaluate the correlation of interleukin 28B (IL28B) genotypes with disease characteristics and demographics in treatment-naïve and treatment-experienced chronic hepatitis C patients, including patients…
- Trial name
- NCT01675427
- Testing
- Interleukin 28B testing
- Where
- 210 sites in United States, Argentina and 29 more
- Volunteers
- 4,766 people
- Sponsor
- Hoffmann-La Roche
Endometriosis
Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life
The study aims to collect data on the influence of a treatment with Visanne (Dienogest 2mg/d) on the Endometriosis related quality of life.
- Trial name
- DIVA (NCT01595724)
- Testing
- Visanne (Dienogest, BAY86-5258)
- Where
- 11 sites in Belarus, Egypt and 9 more
- Volunteers
- 3,006 people
- Sponsor
- Bayer
Protein Allergy, Cow's Milk Protein Hypersensitivity
Efficacy of a New Thickened Extensively Hydrolyzed Formula
Cow Milk Allergy (CMA) occurs in 2 to 5 % of all infants. Reflux, regurgitation and vomiting are well recognised symptoms of CMA. The recommended treatment of CMA is an extensive hydrolysate.
- Trial name
- ALLAR (NCT01985607)
- Testing
- new extensively hydrolysed formula, Extensively hydrolysed formula
- Where
- 5 sites in Belgium, Greece and 3 more
- Volunteers
- 72 people
- Sponsor
- United Pharmaceuticals
Idiopathic Menorrhagia
Mirena in Idiopathic Menorrhagia
This is an open-label, uncontrolled, multi-centre observational study that analyses a follow-up of 1600 women with dysfunctional uterine bleeding (idiopathic menorrhagia) over a period of one year.The patients evaluated at four…
- Trial name
- NCT00868153
- Testing
- Levonorgestrel IUS (Mirena , BAY86-5028)
- Where
- 13 sites in Bulgaria, Croatia and 11 more
- Volunteers
- 1,125 people
- Sponsor
- Bayer
Rheumatoid Arthritis
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
This open-label single-arm study will evaluate the safety, tolerability and efficacy of tocilizumab [RoActemra/Actemra] in patients with moderate to severe rheumatoid arthritis who experience an inadequate clinical response to a…
- Trial name
- NCT01089023
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 9 sites in Bahrain, Iran and 3 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Prostate Cancer
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
This study aims to determine whether early treatment with zoledronic acid, that is given during the early phase of advanced prostate cancer, will be more efficacious than delayed treatment
- Trial name
- NCT00242567
- Testing
- Zoledronic Acid, Androgen Deprivation Therapy (ADT)
- Where
- 27 sites in Australia, Brazil and 8 more
- Volunteers
- 522 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
- Trial name
- EXAMINE (NCT00968708)
- Testing
- Alogliptin
- Where
- 908 sites in United States, Argentina and 48 more
- Volunteers
- 5,380 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 1
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Primary Objective: To evaluate the efficacy of the association Lantus (once-a-day, od) Apidra (thrice-a-day, tid) in terms of change HbA1c from baseline to end of study (week 24), in patients with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- SUBSTITUTE (NCT01204593)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 43 sites in Algeria, Argentina and 7 more
- Volunteers
- 206 people
- Sponsor
- Sanofi
Ovulation Induction
Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction
This is an open-label, prospective, randomized, controlled, multicentric, multinational, phase IV study to evaluate the use of Gonal-f in inducing ovulation in female subjects with chronic anovulation.
- Trial name
- NCT01081626
- Testing
- Recombinant FSH (follitropin alpha)
- Where
- 3 sites in Kuwait, Lebanon and 1 more
- Volunteers
- 310 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hemophilia A
EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS
The aim of this international prospective, non-interventional post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer in treatment of…
- Trial name
- NCT00874926
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- 17 sites in Bahrain, Bosnia and Herzegovina and 15 more
- Volunteers
- 405 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus
Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
To evaluate vildagliptin as compared to gliclazide, given in combination with metformin in Muslim patients with type 2 diabetes fasting during Ramadan.
- Trial name
- STEADFAST (NCT01758380)
- Testing
- Vildagliptin, Gliclazide, Metformin
- Where
- 68 sites in Denmark, Egypt and 14 more
- Volunteers
- 557 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
Primary Objective: To demonstrate the superiority of a strategy with insulin glargine in comparison with a strategy including the premixed insulin in term of percentage of patients reaching HbA1c (glycosylated hemoglobin) below…
- Trial name
- GALAPAGOS (NCT01121835)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE, PREMIXED INSULIN
- Where
- 96 sites in Austria, Brazil and 14 more
- Volunteers
- 934 people
- Sponsor
- Sanofi
Acute Bacterial Sinusitis
Treatment of Patients With Acute Sinusitis
For each patient, an initial visit and at least one follow-up visit at the end of treatment should be documented by the treating physician in the case report form.
- Trial name
- NCT00930488
- Testing
- Avelox (Moxifloxacin, BAY12-8039)
- Where
- 19 sites in Austria, Bahrain and 17 more
- Volunteers
- 6,777 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment
Primary Objective: To demonstrate the superiority of insulin glargine over insulin NPH (Neutral Protamin Hagedornon) the change in HbA1c from baseline to the end of the treatment period.
- Trial name
- LANCELOT (NCT00949442)
- Testing
- Insulin Glargine (HOE901) [Lantus], Glimepiride, human insulin [NPH]
- Where
- 87 sites in Brazil, Czechia and 15 more
- Volunteers
- 708 people
- Sponsor
- Sanofi
Multiple Sclerosis
Physical Activity and Fatigue in Early Multiple Sclerosis (MS)
The purpose of this observational study is to obtain a survey on physical activity in patients who for the first time have experienced symptoms which indicate a high risk for developing multiple sclerosis (MS) and in patients…
- Trial name
- BEGIN (NCT00882453)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 33 sites in Australia, Austria and 31 more
- Volunteers
- 1,739 people
- Sponsor
- Bayer
Contraception
Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)
This study is a prospective, company-sponsored, non-interventional cohort study of up to 5000 patients in European countries and countries in Middle East who are newly prescribed any available OC.
- Trial name
- NCT00905684
- Testing
- EE30/DRSP (Yasmin, BAY86-5131), Any other OC
- Where
- 13 sites in Albania, Bahrain and 11 more
- Volunteers
- 5,446 people
- Sponsor
- Bayer
Hypogonadism
ESPRIT Study in Hypogonadal Men
Observational study with AndroGel®, Testosterone 1% gel therapy (ESPRIT) in hypogonadal men in the community over 6 months.
- Trial name
- NCT01143818
- Testing
- AndroGel (testosterone gel) 1%
- Where
- 331 sites in Canada, Croatia and 7 more
- Volunteers
- 1,053 people
- Sponsor
- Abbott
Diabetes Mellitus, Type 1
Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study
Primary objective : To evaluate the efficacy (in terms of change in HbA1c readings starting from baseline then after 13 weeks \& at the end of the study which will be after 26 weeks) in subjects with type I diabetes mellitus.
- Trial name
- GLANS (NCT00539448)
- Testing
- insulin glargine, insulin glulisine
- Where
- 4 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 98 people
- Sponsor
- Sanofi
Bipolar Disorder
Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study
To assess the efficacy of Di-valproate in Bipolar I patients suffering from a manic episode according to DSM IV (APA 1994) over a 12 weeks period of treatment. To evaluate the clinical safety of Di-valproate.
- Trial name
- GEVANS (NCT00477373)
- Testing
- depakine chrono
- Where
- 4 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 70 people
- Sponsor
- Sanofi